Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group.
Justin FerdinandusLutz van HeekKatrin RothMarkus DietleinHans-Theodor EichChristian BauesPeter BorchmannCarsten KobePublished in: European journal of nuclear medicine and molecular imaging (2023)
PET-2-positive residuals of AS-HL are mostly located in the mediastinum, and a majority of patients have few affected regions. The risk of progression was twofold higher in patients with more than two positive regions in PET-2.
Keyphrases
- phase iii
- open label
- clinical trial
- double blind
- phase ii
- placebo controlled
- pet ct
- positron emission tomography
- computed tomography
- end stage renal disease
- ejection fraction
- pet imaging
- newly diagnosed
- prognostic factors
- hodgkin lymphoma
- chronic kidney disease
- study protocol
- randomized controlled trial
- combination therapy
- replacement therapy